469 filings
6-K
HCM
HUTCHMED (China) Limited
22 Apr 24
Vesting of awards under the Long Term Incentive Plan
6:15am
6-K
HCM
HUTCHMED (China) Limited
8 Apr 24
Current report (foreign)
6:03am
6-K
HCM
HUTCHMED (China) Limited
5 Apr 24
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
6:03am
6-K
HCM
HUTCHMED (China) Limited
2 Apr 24
Current report (foreign)
6:03am
6-K
HCM
HUTCHMED (China) Limited
28 Mar 24
Current report (foreign)
6:02am
6-K
kjw4tw
22 Mar 24
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
6:06am
6-K
fy00wmw2t6
14 Mar 24
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
6:04am
6-K
o61rumnxo0a6
5 Mar 24
Vesting of awards under the Long Term Incentive Plan
6:04am
6-K
1ngdhblsxn75
28 Feb 24
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
6:47am
6-K
8c79emjk3
7 Feb 24
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
6:43am
6-K
fpbq2z vcyjt0b4cfxuj
2 Feb 24
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
6:15am
6-K
822wku2
1 Feb 24
HUTCHMED to Announce 2023 Final Results
6:06am
6-K
7inqqwu
30 Jan 24
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
6:17am
6-K
zkxr gv3xmjr4pl6
11 Jan 24
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
6:02am
6-K
iaho7j
29 Dec 23
Current report (foreign)
6:04am
6-K
ix1hiu7i ks
21 Dec 23
Current report (foreign)
6:14am
6-K
ar7ry 3rwi
13 Dec 23
Current report (foreign)
6:04am
6-K
p2y252 by0e6
7 Dec 23
Current report (foreign)
6:03am
6-K
qud7emq
1 Dec 23
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
6:03am